FOUND: Is dexcom stock underperforming the dow - You Need To See This

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company. It focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems. With a market cap of $27.6 billion, DexCom's operations span the Americas, Europe, and internationally.

Companies worth $10 billion or more are generally described as “large-cap stocks,” DexCom fits the bill perfectly. Given the company’s strong customer base and dominance in the niche space of diabetes, its valuation above this mark is unsurprising. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians.